points, showing an AUC = 0.89; p < 0.0005, sensitivity value of 0.807, specificity of 0.841 and kappa coefficient of agreement with reference clinical diagnosis of 0.65. The scale also showed good concurrent validity with LANSS classification of subjects; kappa 0.61; p < 0.0005. CONCLUSION: The Spanish version of the ID Pain questionnaire is feasible, reliable and appropriated as a self-administered screening tool for pain with a neuropathic component.
(NMP) severe chronic pain treated with intrathecal (IT) analgesia. METHODS: Literature review and in depth interviews with clinical experts (n = 5) led to the development of health state descriptions. These were defined using visual analogue scale of pain intensity (VASPI) ranges 0-40, 41-60, 61-80 and 81-100 for both MP and NMP. Additionally 8 health states representing common adverse events associated with IT therapy were produced. A discussion guide based on the dimensions of the EQ-5D was developed. Health states were piloted with cognitive debriefing with five members of the UK general public. Time trade off interviews were administered to the UK general public (n = 102) to estimate utilities for the health states. A repeated measurement model on the TTO utilities was estimated to account for intrapatient correlation in the data. Using the predicted values from this model, utilities were obtained for all possible VASPI scores. RESULTS: Participants were generally well matched to the census profile of England and Wales with some small differences in mean age, race and education. Utilities ranged from 0.84 for VASPI 0-40 (for NMP & MP) to -0.15 and -0.20 for VASPI 81-100 (NMP & MP respectively). The values for side effects (irrespective of the context of chronic pain) were as follows dizziness (0.40); nausea (0.45); pruritis (0.82); confusional state (0.41); abnormal gait (0.67); urinary retention (0.69); weight gain (0.77) and erectile dysfunction (0.69). The results also show a substantial decline in utility scores related to more severe VASPI values for non-malignant, and malignant disease. CONCLU-SION: The study shows a significant decrement in utility moving from less severe to more severe levels of chronic pain. The general public recognise the very significant impact that severe chronic pain has on HRQL.
PPN12 TURKISH MCGILL PAIN QUESTIONNAIRE: RELIABILITY AND VALIDATION
Oksuz E 1 , Malhan S 1 , Tulunay FC 2 1 Baskent University, Ankara, Turkey, 2 Ankara Uuniversity Medical School, Ankara, Turkey OBJECTIVES: In 1975, Melzack developed the McGill Pain Questionnaire (MPQ), which is composed of four major parts and evaluates the quality of pain. Objective: The aim of this study is to assess the reliability, and validity of the MPQ on a sample of Turkish general population. METHODS: This study used the data from a Web-based questionnaire. This has been administered to 342 participants. RESULTS: The results indicate that the scale is reliable (r = 0.887). Four factors with Eigen values over one have been extracted after evaluating the factor analysis. This has accounted for 62.3% of the variance. Correlations between sensory and evaluative subscales have been low (r = 0.436, p < 0.01), and the most positive correlation has been seen between the miscellaneous and sensory (r = 0.656, p < 0.01), as well as affect subscales (r = 0.601, p < 0.01). Discriminate validity has been evaluated by comparing the patient and control group's scores. For miscellaneous (p = 0.002) and affect (p = 0.006) subscales statistical differences have been found. The correlations between MPQ (subscales and all scale) and Visual Analogue Scale point has been calculated with Spearman correlation for divergent validity. The correlation between VAS and Pain Rating Index for the patient group has been moderate (rho = 0.59, p = 0.000) and low for the control group (rho = 0.32, p = 0.000). For both groups, most strong correlation with the Visual Analogue Scale has been seen for the affect and evaluation subscales of MPQ. CONCLUSION: These results support the Turkish-MPQ as a reliable and valid measure for evaluating the quality of pain in the Turkish population. Turkish MPQ can be used in clinical researches to follow and to evaluate the patients. To evaluate the impact of secondary prophylactic use (PU) of tacrolimus 0.1% ointment on the quality of life (QoL), outcomes and costs in comparison to standard use (SU) of tacrolimus 0.1% ointment in adults with moderate to severe atopic dermatitis (AD) over one year. METHODS: Data were generated as part of a multi-centre, pan-European, phase III clinical trial. Patients were randomised to tacrolimus 0.1% ointment (PU) or vehicle ointment (SU) twice a week, during a 12-month disease control period. In both groups disease exacerbations were treated with tacrolimus 0.1% ointment twice daily. Data on health-related QoL were obtained by using SF-36 questionnaire. Based on these data, utility values were calculated by using the algorithm by Brazier et al. 2002 . Resource consumption data was derived from a patient questionnaire and pooled to estimate the costs using German unit cost data. RESULTS: Seventy-five patients with PU (57% moderately affected) and 59 patients with SU (59% moderately affected) participated. The number of disease exacerbations was 2.4 (PU) vs. 5.5 (SU) (p = 0.0014; moderate AD) and 2.3 (PU) vs. 7.4 (SU) (p = 0.0002; severe AD). Health-related QoL (utility values) in PU patients increased from 0.71 to 0.79 (p = 0.0014; moderate AD) and from 0.66 to 0.75 (p = 0.002; severe AD). In the SU arm utility values increased from 0.69 to 0.72 (NS; moderate AD) and from 0.67 to 0.71 (NS; severe AD). In moderately affected patients mean (SD) total annual cost per patient in the PU arm was €1525 (1081) vs. €1729 (1209) in the SU arm. Mean (SD) total annual cost per patient was €2045 (2013) (PU) vs. €2904 (1,510) (SU) in the group of severely affected patients. CON-Abstracts A467
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PSK1 IMPACT OF SECONDARY PROPHYLACTIC USE OF TACROLIMUS 0.1% OINTMENT ON QUALITY-OF-LIFE, TREATMENT OUTCOMES AND COSTS IN PATIENTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS
